Your Messages Inbox
Your Article Summary
See Latest ArticlesNew study demonstrated actemra (tocilizumab) inhibited progression of joint damage in rheumatoid arthritis patients
Roche, 10/29/08
One-year data from a two-year Phase III study demonstrated that ACTEMRA (tocilizumab) significantly inhibited the progression of structural joint damage in patients with rheumatoid arthritis (RA). Late-breaking results from the LITHE study will be featured as an oral presentation during the American College of Rheumatology (ACR) Annual Scientific Meeting (October 24-28) in San Francisco. Fourteen additional abstracts, which evaluate ACTEMRA, a novel interleukin-6 (IL-6) receptor inhibitor, in patients with moderately to severely active RA, will also be presented during the meeting.
Today in Marketing/Media/ROI...keeping you current
Receive free subspecialty "5-minute updates" via email
Watson Announces Agreement to Acquire U.S. Rights to Columbia Laboratories CRINONE(R) Progesterone Gel Product Line
Watson Pharmaceuticals, 03/05/10
Report Predicts Major Slowdown for Big Pharma
PharmExec, 03/05/10
Astellas Hostile Takeover Turns Even More Hostile
PharmExec, 03/04/10
Article Search
Sponsor